Diabetic Peripheral Neuropathy Pipeline Sees Expansion Owing to Key Players, Key Therapies and Research & Programmes

"DelveInsight's Diabetic Peripheral Neuropathy Pipeline Insights 2022 report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Diabetic Peripheral Neuropathy pipeline landscape"

DelveInsight's Diabetic Peripheral Neuropathy Pipeline Insights 2023 report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Diabetic Peripheral Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from Diabetic Peripheral Neuropathy Pipeline Report
• Diabetic Peripheral Neuropathy Pipeline report offers a comprehensive analysis of 20+ companies and 20+ therapies.
• The Diabetic Peripheral Neuropathy Pipeline Report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Peripheral Neuropathy therapeutic drugs key players involved in developing key drugs.
• Diabetic Peripheral Neuropathy Emerging Therapies included such as CSPC ZhongQi Pharmaceutical Technology Co., Ltd, Helixmith, Aptinyx, Lexicon Pharmaceuticals, and several others.
• Diabetic Peripheral Neuropathy Pipeline Companies included such as Lexicon Pharmaceuticals, Lateral Pharma Pty Ltd., SIMR (Australia) Biotech Pty Ltd., WinSanTor, Inc., Eli Lilly and Company, Daiichi Sankyo, Inc., Avazzia, Inc., and several others.

Download a PDF Sample Copy of the Diabetic Peripheral Neuropathy Clinical Trials Report, visit here- https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diabetic Peripheral Neuropathy Overview
Diabetic neuropathy is nerve damage caused by diabetes. When it affects the arms, hands, legs and feet, it is known as diabetic peripheral neuropathy.Diabetic peripheral neuropathy is different from peripheral arterial disease (poor circulation), which affects the blood vessels rather than the nerves. Three different groups of nerves can be affected by diabetic neuropathy:
• Sensory nerves, which enable people to feel pain, temperature and other sensations
• Motor nerves, which control the muscles and give them their strength and tone
• Autonomic nerves, which allow the body to perform certain involuntary functions, such as sweating

Diabetic Peripheral Neuropathy Treatment
First and foremost, treatment of diabetic peripheral neuropathy centers on control of the patient's blood sugar level. In addition, various options are used to treat the painful symptoms. Medications are available to help relieve specific symptoms, such as tingling or burning. Sometimes a combination of different medications is used. In some cases, the patient may also undergo physical therapy to help reduce balance problems or other symptoms.

Diabetic Peripheral Neuropathy Emerging Drugs

• FE-SYHA1402: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
ZhongQi Pharmaceutical Technology is conducting a multiple doses study to evaluate the safety, tolerability, pharmacokinetics (including food effect) of SYHA1402 in healthy subjects. This study consists of two parts: The objective of the food effect study (Part 1) is to investigate the effect of food on the pharmacokinetic profiles of SYHA1402 tablets under fed and fasted conditions following the oral administration of SYHA1402. The primary objective of the multiple doses study (Part 2) is to investigate safety, tolerability and Pharmacokinetics of SYHA1402 in healthy subjects following oral administration of Multiple rising doses. Secondary objectives are the exploration of pharmacokinetics (PK) following multiple oral doses.

• VM202: Helixmith
VM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy. VM202 is a novel genomic cDNA hybrid human hepatocyte growth factor (HGF) gene with a novel and proprietary coding sequence (HGF-X7) expressing two isoforms - a configuration that closely mimics HGF productions in humans that is needed for optimal therapeutic benefits. Because there is no change in the coding region of the HGF gene, HGF proteins generated from VM202 are identical to wildtype human HGF proteins.

• NYX-2925: Aptinyx
NYX-2925 is a novel, oral small molecule NMDA receptor modulator in development for the treatment of chronic pain. Dysregulation of glutamatergic circuits in the brain is involved in the development of centralized chronic pain. NYX-2925 is in late stage clinical development across two chronic pain indications -Painful Diabetic Peripheral Neuropathy and Fibromyalgia.

• LX9211: Lexicon Pharmaceuticals
LX9211 is a potent, orally delivered, selective small molecule inhibitor of AAK1, a target discovered and extensively characterized in an alliance with Bristol Myers Squibb. Preclinical data demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain. Lexicon has exclusive research, development and commercialization rights to LX9211 and additional compounds acting through AAK1.

Get to know more information of the Diabetic Peripheral Neuropathy Emerging Therapies and Companies- https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diabetic Peripheral Neuropathy Pipeline Phases
DelveInsight's report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase II and Phase II/III)
• Mid-stage products (Phase II and Phase II/III)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Diabetic Peripheral Neuropathy Pipeline Analysis
The report provides insights into:-
• The report provides detailed insights about companies that are developing therapies in the Diabetic Peripheral Neuropathy Market.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Peripheral Neuropathy treatment.
• Diabetic Peripheral Neuropathy key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Diabetic Peripheral Neuropathy Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Diabetic Peripheral Neuropathy market.

Diabetic Peripheral Neuropathy Pipeline Therapeutic Analysis
There are approx. 20+ key companies which are developing the therapies for Diabetic Peripheral Neuropathy. The companies which have their Diabetic Peripheral Neuropathy drug candidates in the most advanced stage, i.e. phase III include, Helixmith Co., Ltd. and Daiichi Sankyo.

Scope of the Diabetic Peripheral Neuropathy Pipeline Report
• Coverage- Global
• Diabetic Peripheral Neuropathy Emerging Therapies included such as CSPC ZhongQi Pharmaceutical Technology Co., Ltd, Helixmith, Aptinyx, Lexicon Pharmaceuticals, and several others.
• Diabetic Peripheral Neuropathy Pipeline Companies included such as Lexicon Pharmaceuticals, Lateral Pharma Pty Ltd., SIMR (Australia) Biotech Pty Ltd., WinSanTor, Inc., Eli Lilly and Company, Daiichi Sankyo, Inc., Avazzia, Inc., and several others.

To know more facts about the Diabetic Peripheral Neuropathy Pipeline Insights Report, View Here- https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Diabetic Peripheral Neuropathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diabetic Peripheral Neuropathy - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Diabetic Peripheral Neuropathy Collaboration Deals
9. Late Stage Products (Phase III)
10. Engensis: Helixmith Co., Ltd.
11. Mid Stage Products (Phase II)
12. Aptinyx: NYX-2925
13. LX9211: Lexicon Pharmaceuticals
14. FE-SYHA1402: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
15. SR419: SIMR (Australia) Biotech Pty Ltd.
16. Inactive Products
17. Comparative Analysis
18. Diabetic Peripheral Neuropathy- Market Drivers and Barriers
19. Appendix

For any query related to the Diabetic Peripheral Neuropathy Pipeline Report, then speak to the analyst here- https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.